Shares of$联拓生物(LIAN.US)$— which focuses on “developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries” — are soaring on Tuesday. Earlier this morning, the company announced a key agreement with$ブリストル・マイヤーズ スクイブ(BMY.US)$regarding exclusive rights to a cardiovascular therapeutic. Subsequently, LIAN stock is up more than 130% as of this writing. According to the ac...
$モデルナ(MRNA.US)$ This was a sale that was planned ahead of time by the CEO of Moderna. It was not a random sale on the open market. But a few things to take away from this SEC filing. The transaction was planned to happen after the first half of the year during quad witching where repositioning volume is at its peak. This was a very large transaction and the CEO was only disposing shares of Moderna. There were a couple conversions of stock options but thery we...
Gainers: •$イノヴィズ・テクノロジーズ(INVZ.US)$+18.7% (selected by "large automotive group manufacturer" to become its direct LiDAR supplier across multiple brands) •$ヒルトップ・ホールディングス(HTH.US)$+15.7% (commenced a modified "Dutch auction" tender offer to purchase for cash up to $400 mln of its common stock at a price per share not less than $28,00 and not greater than $32.00 less any applicable withholding taxes and without interest usin...
18
3
2
報告
Dino 64 :
Nio is a pre market mover alright.....DOWN.
Gainers: •$クロビス・オンコロジー(CLVS.US)$+40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial) •$デア・バイオサイエンス(DARE.US)$+13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO) •$クーラー・テクノロジー・グループ(KULR.US)$+9.5% (secured a battery sa...
HUTCHMEDに関するコメント
Biotech Stock Catalyst Watchlist
$イントラセルラー・セラピーズ(ITCI.US)$ Phase 3
$CG Oncology(CGON.US)$ Phase 3
$ハチメド・チャイナ(HCM.US)$ Phase 3
$ビラクタ・セラピューティクス(VIRX.US)$ Phase 3
$グリコミメティクス(GLYC.US)$ Phase 3
$アネクソン(ANNX.US)$ Phase 3
$リポシン(LPCN.US)$ Phase 3
$ファイブロジェン(FGEN.US)$ Phase 3
$ユーロジェン・ファーマ(URGN.US)$ Phase 3
$ライラ・セラピューティクス(LYRA.US)$ Phase 3
$シティアス・ファーマシューティカルズ(CTXR.US)$ Phase 3
$マリナス・ファーマシューティカルズ(MRNS.US)$ Phase 3
$バイオカーディア(BCDA.US)$ Phase 3...
Why Is LianBio (LIAN) Stock Up 130% Today?
According to the ac...
market open watch this potential halt up monster
コラムToday's pre-market stock movers: PLTR, BBBY, BNTX, GOLD and more
In reaction to earnings/guidance:
• $Karuna Therapeutics(KRTX.US)$ +42.6% (also reports topline results from its Phase3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT), $マンデー・ドット・コム(MNDY.US)$ +15.1%,$W&Tオフショア(WTI.US)$ +6.7%,$HFシンクレア(DINO.US)$ +5.3%,$ヴィアトリス(VTRS.US)$ +4.3%,$コスモス・エナジー(KOS.US)$ + 3.2%,$Holly Energy(HEP.US)$ +3.2%,$バリック・ゴールド(GOLD.US)$ +2.9%,...
Big Repositioning on Witching Day
This was a sale that was planned ahead of time by the CEO of Moderna. It was not a random sale on the open market. But a few things to take away from this SEC filing. The transaction was planned to happen after the first half of the year during quad witching where repositioning volume is at its peak. This was a very large transaction and the CEO was only disposing shares of Moderna. There were a couple conversions of stock options but thery we...
コラムToday's pre-market stock movers: CRM, WB, LI, NIO and more
• $ヴィクトリアズ・シークレット(VSCO.US)$ +10.4% (In reaction to earnings)
• $セールスフォース(CRM.US)$ +9.0% (In reaction to earnings)
• $ナビゲーター・ホールディングス(NVGS.US)$ +4.9% (names Mads Peter Zacho as CEO)
• $ウェイボー(WB.US)$ +4.7% (In reaction to earnings)
• $CAE(CAE.US)$ +4.7% (In reaction to earnings)
• $Laredo Petroleum(LPI.US)$ +4% (authorized $200 mln share repurchase program)
• $アクサム・セラピューティクス(AXSM.US)$ +3.1% (Late-Breaking Presentations of P...
コラムToday's pre-market stock movers: JELD, BILI, NIO, XPEV and more
• $イノヴィズ・テクノロジーズ(INVZ.US)$ +18.7% (selected by "large automotive group manufacturer" to become its direct LiDAR supplier across multiple brands)
• $ヒルトップ・ホールディングス(HTH.US)$ +15.7% (commenced a modified "Dutch auction" tender offer to purchase for cash up to $400 mln of its common stock at a price per share not less than $28,00 and not greater than $32.00 less any applicable withholding taxes and without interest usin...
コラムToday's pre-market stock movers: CLVS, PATH, DARE and more
• $クロビス・オンコロジー(CLVS.US)$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $デア・バイオサイエンス(DARE.US)$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $クーラー・テクノロジー・グループ(KULR.US)$ +9.5% (secured a battery sa...
まだコメントはありません